USD 1.35
(-1.01%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 96.39 Thousand USD | 75.02% |
2022 | 55.07 Thousand USD | 0.0% |
2021 | - USD | -100.0% |
2020 | 71.87 Thousand USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 4.03 Million USD | 4082.5% |
2024 Q2 | 2.6 Million USD | -35.42% |
2023 FY | 96.39 Thousand USD | 75.02% |
2023 Q2 | 81.89 Thousand USD | 68.48% |
2023 Q1 | 48.6 Thousand USD | -11.74% |
2023 Q3 | 22.78 Thousand USD | -72.18% |
2023 Q4 | 96.39 Thousand USD | 323.03% |
2022 Q4 | 55.07 Thousand USD | -99.88% |
2022 Q3 | 44.46 Million USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
AIM ImmunoTech Inc. | 19.38 Million USD | 99.503% |
Ampio Pharmaceuticals, Inc. | 5.73 Million USD | 98.32% |
Armata Pharmaceuticals, Inc. | 109.96 Million USD | 99.912% |
Actinium Pharmaceuticals, Inc. | 81.44 Million USD | 99.882% |
Azitra, Inc. | 5.11 Million USD | 98.116% |
Can-Fite BioPharma Ltd. | 9.98 Million USD | 99.035% |
Calidi Biotherapeutics, Inc. | 10.01 Million USD | 99.038% |
CEL-SCI Corporation | 30.52 Million USD | 99.684% |
iBio, Inc. | 28.73 Million USD | 99.665% |
Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 99.905% |
MAIA Biotechnology, Inc. | 7.56 Million USD | 98.726% |
Matinas BioPharma Holdings, Inc. | 65.57 Million USD | 99.853% |
Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | 97.795% |
NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | 98.933% |
NanoViricides, Inc. | 12.82 Million USD | 99.248% |
Oragenics, Inc. | 4.96 Million USD | 98.059% |
BiomX Inc. | 58.15 Million USD | 99.834% |
BiomX Inc. | 58.15 Million USD | 99.834% |
Protalix BioTherapeutics, Inc. | 84.43 Million USD | 99.886% |
Palatin Technologies, Inc. | 10.74 Million USD | 99.103% |
Scorpius Holdings, Inc. | 51.03 Million USD | 99.811% |
Theriva Biologics, Inc. | 60.21 Million USD | 99.84% |